 | • レポートコード：MRC2-11QY02728 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、146ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は心房細動薬のグローバル市場について調査・分析したレポートです。種類別（抗不整脈薬、抗凝固薬）市場規模、用途別（発作性心房細動、持続性心房細動、長年の持続性心房細動）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別心房細動薬の競争状況、市場シェア ・世界の心房細動薬市場：種類別市場規模 2015年-2020年（抗不整脈薬、抗凝固薬） ・世界の心房細動薬市場：種類別市場規模予測 2021年-2026年（抗不整脈薬、抗凝固薬） ・世界の心房細動薬市場：用途別市場規模 2015年-2020年（発作性心房細動、持続性心房細動、長年の持続性心房細動） ・世界の心房細動薬市場：用途別市場規模予測 2021年-2026年（発作性心房細動、持続性心房細動、長年の持続性心房細動） ・北米の心房細動薬市場分析：米国、カナダ ・ヨーロッパの心房細動薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの心房細動薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の心房細動薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの心房細動薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Boehringer Ingelheim、Janssen Pharmaceuticals、Sanofi、ARCA Biopharma、Armetheon、Baxter、Bristol-Myers Squibb、ChanRx、Daiichi Sankyo、Gilead Sciences、HUYA Biosciences、Menarini、Pfizer、Pierre Fabre、Servier、Xention ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Atrial Fibrillation Drugs Market
The global Atrial Fibrillation Drugs market size is projected to reach US$ 6158 million by 2026, from US$ 5987 million in 2020, at a CAGR of 2.7%% during 2021-2026.
Global Atrial Fibrillation Drugs Scope and Market Size
Atrial Fibrillation Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Atrial Fibrillation Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Atrial Fibrillation Drugs market is segmented into
Anti-Arrhythmic Drugs
Anti-Coagulant Drugs
Segment by Application, the Atrial Fibrillation Drugs market is segmented into
Paroxysmal Atrial Fibrillation
Persistent Atrial Fibrillation
Longstanding Persistent Afib
Regional and Country-level Analysis
The Atrial Fibrillation Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Atrial Fibrillation Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Atrial Fibrillation Drugs Market Share Analysis
Atrial Fibrillation Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Atrial Fibrillation Drugs business, the date to enter into the Atrial Fibrillation Drugs market, Atrial Fibrillation Drugs product introduction, recent developments, etc.
The major vendors covered:
Boehringer Ingelheim
Janssen Pharmaceuticals
Sanofi
ARCA Biopharma
Armetheon
Baxter
Bristol-Myers Squibb
ChanRx
Daiichi Sankyo
Gilead Sciences
HUYA Biosciences
Menarini
Pfizer
Pierre Fabre
Servier
Xention
1 Study Coverage
1.1 Atrial Fibrillation Drugs Product Introduction
1.2 Market Segments
1.3 Key Atrial Fibrillation Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Atrial Fibrillation Drugs Market Size Growth Rate by Type
1.4.2 Anti-Arrhythmic Drugs
1.4.3 Anti-Coagulant Drugs
1.5 Market by Application
1.5.1 Global Atrial Fibrillation Drugs Market Size Growth Rate by Application
1.5.2 Paroxysmal Atrial Fibrillation
1.5.3 Persistent Atrial Fibrillation
1.5.4 Longstanding Persistent Afib
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Atrial Fibrillation Drugs Market Size, Estimates and Forecasts
2.1.1 Global Atrial Fibrillation Drugs Revenue 2015-2026
2.1.2 Global Atrial Fibrillation Drugs Sales 2015-2026
2.2 Global Atrial Fibrillation Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Atrial Fibrillation Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Atrial Fibrillation Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Atrial Fibrillation Drugs Competitor Landscape by Players
3.1 Atrial Fibrillation Drugs Sales by Manufacturers
3.1.1 Atrial Fibrillation Drugs Sales by Manufacturers (2015-2020)
3.1.2 Atrial Fibrillation Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Atrial Fibrillation Drugs Revenue by Manufacturers
3.2.1 Atrial Fibrillation Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Atrial Fibrillation Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Atrial Fibrillation Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Atrial Fibrillation Drugs Revenue in 2019
3.2.5 Global Atrial Fibrillation Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Atrial Fibrillation Drugs Price by Manufacturers
3.4 Atrial Fibrillation Drugs Manufacturing Base Distribution, Product Types
3.4.1 Atrial Fibrillation Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Atrial Fibrillation Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Atrial Fibrillation Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Atrial Fibrillation Drugs Market Size by Type (2015-2020)
4.1.1 Global Atrial Fibrillation Drugs Sales by Type (2015-2020)
4.1.2 Global Atrial Fibrillation Drugs Revenue by Type (2015-2020)
4.1.3 Atrial Fibrillation Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Atrial Fibrillation Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Atrial Fibrillation Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Atrial Fibrillation Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Atrial Fibrillation Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Atrial Fibrillation Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Atrial Fibrillation Drugs Market Size by Application (2015-2020)
5.1.1 Global Atrial Fibrillation Drugs Sales by Application (2015-2020)
5.1.2 Global Atrial Fibrillation Drugs Revenue by Application (2015-2020)
5.1.3 Atrial Fibrillation Drugs Price by Application (2015-2020)
5.2 Atrial Fibrillation Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Atrial Fibrillation Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Atrial Fibrillation Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Atrial Fibrillation Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Atrial Fibrillation Drugs by Country
6.1.1 North America Atrial Fibrillation Drugs Sales by Country
6.1.2 North America Atrial Fibrillation Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Atrial Fibrillation Drugs Market Facts & Figures by Type
6.3 North America Atrial Fibrillation Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Atrial Fibrillation Drugs by Country
7.1.1 Europe Atrial Fibrillation Drugs Sales by Country
7.1.2 Europe Atrial Fibrillation Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Atrial Fibrillation Drugs Market Facts & Figures by Type
7.3 Europe Atrial Fibrillation Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Atrial Fibrillation Drugs by Region
8.1.1 Asia Pacific Atrial Fibrillation Drugs Sales by Region
8.1.2 Asia Pacific Atrial Fibrillation Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Atrial Fibrillation Drugs Market Facts & Figures by Type
8.3 Asia Pacific Atrial Fibrillation Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Atrial Fibrillation Drugs by Country
9.1.1 Latin America Atrial Fibrillation Drugs Sales by Country
9.1.2 Latin America Atrial Fibrillation Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Atrial Fibrillation Drugs Market Facts & Figures by Type
9.3 Central & South America Atrial Fibrillation Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Atrial Fibrillation Drugs by Country
10.1.1 Middle East and Africa Atrial Fibrillation Drugs Sales by Country
10.1.2 Middle East and Africa Atrial Fibrillation Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Atrial Fibrillation Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Atrial Fibrillation Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Corporation Information
11.1.2 Boehringer Ingelheim Description and Business Overview
11.1.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Boehringer Ingelheim Atrial Fibrillation Drugs Products Offered
11.1.5 Boehringer Ingelheim Related Developments
11.2 Janssen Pharmaceuticals
11.2.1 Janssen Pharmaceuticals Corporation Information
11.2.2 Janssen Pharmaceuticals Description and Business Overview
11.2.3 Janssen Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Janssen Pharmaceuticals Atrial Fibrillation Drugs Products Offered
11.2.5 Janssen Pharmaceuticals Related Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Description and Business Overview
11.3.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Sanofi Atrial Fibrillation Drugs Products Offered
11.3.5 Sanofi Related Developments
11.4 ARCA Biopharma
11.4.1 ARCA Biopharma Corporation Information
11.4.2 ARCA Biopharma Description and Business Overview
11.4.3 ARCA Biopharma Sales, Revenue and Gross Margin (2015-2020)
11.4.4 ARCA Biopharma Atrial Fibrillation Drugs Products Offered
11.4.5 ARCA Biopharma Related Developments
11.5 Armetheon
11.5.1 Armetheon Corporation Information
11.5.2 Armetheon Description and Business Overview
11.5.3 Armetheon Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Armetheon Atrial Fibrillation Drugs Products Offered
11.5.5 Armetheon Related Developments
11.6 Baxter
11.6.1 Baxter Corporation Information
11.6.2 Baxter Description and Business Overview
11.6.3 Baxter Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Baxter Atrial Fibrillation Drugs Products Offered
11.6.5 Baxter Related Developments
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Corporation Information
11.7.2 Bristol-Myers Squibb Description and Business Overview
11.7.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Bristol-Myers Squibb Atrial Fibrillation Drugs Products Offered
11.7.5 Bristol-Myers Squibb Related Developments
11.8 ChanRx
11.8.1 ChanRx Corporation Information
11.8.2 ChanRx Description and Business Overview
11.8.3 ChanRx Sales, Revenue and Gross Margin (2015-2020)
11.8.4 ChanRx Atrial Fibrillation Drugs Products Offered
11.8.5 ChanRx Related Developments
11.9 Daiichi Sankyo
11.9.1 Daiichi Sankyo Corporation Information
11.9.2 Daiichi Sankyo Description and Business Overview
11.9.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Daiichi Sankyo Atrial Fibrillation Drugs Products Offered
11.9.5 Daiichi Sankyo Related Developments
11.10 Gilead Sciences
11.10.1 Gilead Sciences Corporation Information
11.10.2 Gilead Sciences Description and Business Overview
11.10.3 Gilead Sciences Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Gilead Sciences Atrial Fibrillation Drugs Products Offered
11.10.5 Gilead Sciences Related Developments
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Corporation Information
11.1.2 Boehringer Ingelheim Description and Business Overview
11.1.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Boehringer Ingelheim Atrial Fibrillation Drugs Products Offered
11.1.5 Boehringer Ingelheim Related Developments
11.12 Menarini
11.12.1 Menarini Corporation Information
11.12.2 Menarini Description and Business Overview
11.12.3 Menarini Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Menarini Products Offered
11.12.5 Menarini Related Developments
11.13 Pfizer
11.13.1 Pfizer Corporation Information
11.13.2 Pfizer Description and Business Overview
11.13.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Pfizer Products Offered
11.13.5 Pfizer Related Developments
11.14 Pierre Fabre
11.14.1 Pierre Fabre Corporation Information
11.14.2 Pierre Fabre Description and Business Overview
11.14.3 Pierre Fabre Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Pierre Fabre Products Offered
11.14.5 Pierre Fabre Related Developments
11.15 Servier
11.15.1 Servier Corporation Information
11.15.2 Servier Description and Business Overview
11.15.3 Servier Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Servier Products Offered
11.15.5 Servier Related Developments
11.16 Xention
11.16.1 Xention Corporation Information
11.16.2 Xention Description and Business Overview
11.16.3 Xention Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Xention Products Offered
11.16.5 Xention Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Atrial Fibrillation Drugs Market Estimates and Projections by Region
12.1.1 Global Atrial Fibrillation Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Atrial Fibrillation Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Atrial Fibrillation Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Atrial Fibrillation Drugs Sales Forecast (2021-2026)
12.2.2 North America: Atrial Fibrillation Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Atrial Fibrillation Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Atrial Fibrillation Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Atrial Fibrillation Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Atrial Fibrillation Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Atrial Fibrillation Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Atrial Fibrillation Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Atrial Fibrillation Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Atrial Fibrillation Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Atrial Fibrillation Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Atrial Fibrillation Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Atrial Fibrillation Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Atrial Fibrillation Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Atrial Fibrillation Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Atrial Fibrillation Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Atrial Fibrillation Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Atrial Fibrillation Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Atrial Fibrillation Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Atrial Fibrillation Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Atrial Fibrillation Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Atrial Fibrillation Drugs Market Segments
Table 2. Ranking of Global Top Atrial Fibrillation Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Atrial Fibrillation Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Anti-Arrhythmic Drugs
Table 5. Major Manufacturers of Anti-Coagulant Drugs
Table 6. Global Atrial Fibrillation Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 7. Global Atrial Fibrillation Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 8. Global Atrial Fibrillation Drugs Sales by Regions 2015-2020 (K MT)
Table 9. Global Atrial Fibrillation Drugs Sales Market Share by Regions (2015-2020)
Table 10. Global Atrial Fibrillation Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Atrial Fibrillation Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 12. Global Atrial Fibrillation Drugs Sales Share by Manufacturers (2015-2020)
Table 13. Global Atrial Fibrillation Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Atrial Fibrillation Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Atrial Fibrillation Drugs as of 2019)
Table 15. Atrial Fibrillation Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Atrial Fibrillation Drugs Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Atrial Fibrillation Drugs Price (2015-2020) (USD/MT)
Table 18. Atrial Fibrillation Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Atrial Fibrillation Drugs Product Type
Table 20. Date of International Manufacturers Enter into Atrial Fibrillation Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Atrial Fibrillation Drugs Sales by Type (2015-2020) (K MT)
Table 23. Global Atrial Fibrillation Drugs Sales Share by Type (2015-2020)
Table 24. Global Atrial Fibrillation Drugs Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Atrial Fibrillation Drugs Revenue Share by Type (2015-2020)
Table 26. Atrial Fibrillation Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 27. Global Atrial Fibrillation Drugs Sales by Application (2015-2020) (K MT)
Table 28. Global Atrial Fibrillation Drugs Sales Share by Application (2015-2020)
Table 29. North America Atrial Fibrillation Drugs Sales by Country (2015-2020) (K MT)
Table 30. North America Atrial Fibrillation Drugs Sales Market Share by Country (2015-2020)
Table 31. North America Atrial Fibrillation Drugs Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Atrial Fibrillation Drugs Revenue Market Share by Country (2015-2020)
Table 33. North America Atrial Fibrillation Drugs Sales by Type (2015-2020) (K MT)
Table 34. North America Atrial Fibrillation Drugs Sales Market Share by Type (2015-2020)
Table 35. North America Atrial Fibrillation Drugs Sales by Application (2015-2020) (K MT)
Table 36. North America Atrial Fibrillation Drugs Sales Market Share by Application (2015-2020)
Table 37. Europe Atrial Fibrillation Drugs Sales by Country (2015-2020) (K MT)
Table 38. Europe Atrial Fibrillation Drugs Sales Market Share by Country (2015-2020)
Table 39. Europe Atrial Fibrillation Drugs Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Atrial Fibrillation Drugs Revenue Market Share by Country (2015-2020)
Table 41. Europe Atrial Fibrillation Drugs Sales by Type (2015-2020) (K MT)
Table 42. Europe Atrial Fibrillation Drugs Sales Market Share by Type (2015-2020)
Table 43. Europe Atrial Fibrillation Drugs Sales by Application (2015-2020) (K MT)
Table 44. Europe Atrial Fibrillation Drugs Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Atrial Fibrillation Drugs Sales by Region (2015-2020) (K MT)
Table 46. Asia Pacific Atrial Fibrillation Drugs Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Atrial Fibrillation Drugs Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Atrial Fibrillation Drugs Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Atrial Fibrillation Drugs Sales by Type (2015-2020) (K MT)
Table 50. Asia Pacific Atrial Fibrillation Drugs Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Atrial Fibrillation Drugs Sales by Application (2015-2020) (K MT)
Table 52. Asia Pacific Atrial Fibrillation Drugs Sales Market Share by Application (2015-2020)
Table 53. Latin America Atrial Fibrillation Drugs Sales by Country (2015-2020) (K MT)
Table 54. Latin America Atrial Fibrillation Drugs Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Atrial Fibrillation Drugs Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Atrial Fibrillation Drugs Revenue Market Share by Country (2015-2020)
Table 57. Latin America Atrial Fibrillation Drugs Sales by Type (2015-2020) (K MT)
Table 58. Latin America Atrial Fibrillation Drugs Sales Market Share by Type (2015-2020)
Table 59. Latin America Atrial Fibrillation Drugs Sales by Application (2015-2020) (K MT)
Table 60. Latin America Atrial Fibrillation Drugs Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Atrial Fibrillation Drugs Sales by Country (2015-2020) (K MT)
Table 62. Middle East and Africa Atrial Fibrillation Drugs Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Atrial Fibrillation Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Atrial Fibrillation Drugs Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Atrial Fibrillation Drugs Sales by Type (2015-2020) (K MT)
Table 66. Middle East and Africa Atrial Fibrillation Drugs Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Atrial Fibrillation Drugs Sales by Application (2015-2020) (K MT)
Table 68. Middle East and Africa Atrial Fibrillation Drugs Sales Market Share by Application (2015-2020)
Table 69. Boehringer Ingelheim Corporation Information
Table 70. Boehringer Ingelheim Description and Major Businesses
Table 71. Boehringer Ingelheim Atrial Fibrillation Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 72. Boehringer Ingelheim Product
Table 73. Boehringer Ingelheim Recent Development
Table 74. Janssen Pharmaceuticals Corporation Information
Table 75. Janssen Pharmaceuticals Description and Major Businesses
Table 76. Janssen Pharmaceuticals Atrial Fibrillation Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. Janssen Pharmaceuticals Product
Table 78. Janssen Pharmaceuticals Recent Development
Table 79. Sanofi Corporation Information
Table 80. Sanofi Description and Major Businesses
Table 81. Sanofi Atrial Fibrillation Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. Sanofi Product
Table 83. Sanofi Recent Development
Table 84. ARCA Biopharma Corporation Information
Table 85. ARCA Biopharma Description and Major Businesses
Table 86. ARCA Biopharma Atrial Fibrillation Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. ARCA Biopharma Product
Table 88. ARCA Biopharma Recent Development
Table 89. Armetheon Corporation Information
Table 90. Armetheon Description and Major Businesses
Table 91. Armetheon Atrial Fibrillation Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 92. Armetheon Product
Table 93. Armetheon Recent Development
Table 94. Baxter Corporation Information
Table 95. Baxter Description and Major Businesses
Table 96. Baxter Atrial Fibrillation Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 97. Baxter Product
Table 98. Baxter Recent Development
Table 99. Bristol-Myers Squibb Corporation Information
Table 100. Bristol-Myers Squibb Description and Major Businesses
Table 101. Bristol-Myers Squibb Atrial Fibrillation Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 102. Bristol-Myers Squibb Product
Table 103. Bristol-Myers Squibb Recent Development
Table 104. ChanRx Corporation Information
Table 105. ChanRx Description and Major Businesses
Table 106. ChanRx Atrial Fibrillation Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 107. ChanRx Product
Table 108. ChanRx Recent Development
Table 109. Daiichi Sankyo Corporation Information
Table 110. Daiichi Sankyo Description and Major Businesses
Table 111. Daiichi Sankyo Atrial Fibrillation Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 112. Daiichi Sankyo Product
Table 113. Daiichi Sankyo Recent Development
Table 114. Gilead Sciences Corporation Information
Table 115. Gilead Sciences Description and Major Businesses
Table 116. Gilead Sciences Atrial Fibrillation Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Gilead Sciences Product
Table 118. Gilead Sciences Recent Development
Table 119. HUYA Biosciences Corporation Information
Table 120. HUYA Biosciences Description and Major Businesses
Table 121. HUYA Biosciences Atrial Fibrillation Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 122. HUYA Biosciences Product
Table 123. HUYA Biosciences Recent Development
Table 124. Menarini Corporation Information
Table 125. Menarini Description and Major Businesses
Table 126. Menarini Atrial Fibrillation Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 127. Menarini Product
Table 128. Menarini Recent Development
Table 129. Pfizer Corporation Information
Table 130. Pfizer Description and Major Businesses
Table 131. Pfizer Atrial Fibrillation Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 132. Pfizer Product
Table 133. Pfizer Recent Development
Table 134. Pierre Fabre Corporation Information
Table 135. Pierre Fabre Description and Major Businesses
Table 136. Pierre Fabre Atrial Fibrillation Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 137. Pierre Fabre Product
Table 138. Pierre Fabre Recent Development
Table 139. Servier Corporation Information
Table 140. Servier Description and Major Businesses
Table 141. Servier Atrial Fibrillation Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 142. Servier Product
Table 143. Servier Recent Development
Table 144. Xention Corporation Information
Table 145. Xention Description and Major Businesses
Table 146. Xention Atrial Fibrillation Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 147. Xention Product
Table 148. Xention Recent Development
Table 149. Global Atrial Fibrillation Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 150. Global Atrial Fibrillation Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 151. Global Atrial Fibrillation Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 152. Global Atrial Fibrillation Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 153. North America: Atrial Fibrillation Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 154. North America: Atrial Fibrillation Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 155. Europe: Atrial Fibrillation Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 156. Europe: Atrial Fibrillation Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 157. Asia Pacific: Atrial Fibrillation Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 158. Asia Pacific: Atrial Fibrillation Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 159. Latin America: Atrial Fibrillation Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 160. Latin America: Atrial Fibrillation Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 161. Middle East and Africa: Atrial Fibrillation Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 162. Middle East and Africa: Atrial Fibrillation Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 163. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 164. Key Challenges
Table 165. Market Risks
Table 166. Main Points Interviewed from Key Atrial Fibrillation Drugs Players
Table 167. Atrial Fibrillation Drugs Customers List
Table 168. Atrial Fibrillation Drugs Distributors List
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Atrial Fibrillation Drugs Product Picture
Figure 2. Global Atrial Fibrillation Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Anti-Arrhythmic Drugs Product Picture
Figure 4. Anti-Coagulant Drugs Product Picture
Figure 5. Global Atrial Fibrillation Drugs Sales Market Share by Application in 2020 & 2026
Figure 6. Paroxysmal Atrial Fibrillation
Figure 7. Persistent Atrial Fibrillation
Figure 8. Longstanding Persistent Afib
Figure 9. Atrial Fibrillation Drugs Report Years Considered
Figure 10. Global Atrial Fibrillation Drugs Market Size 2015-2026 (US$ Million)
Figure 11. Global Atrial Fibrillation Drugs Sales 2015-2026 (K MT)
Figure 12. Global Atrial Fibrillation Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 13. Global Atrial Fibrillation Drugs Sales Market Share by Region (2015-2020)
Figure 14. Global Atrial Fibrillation Drugs Sales Market Share by Region in 2019
Figure 15. Global Atrial Fibrillation Drugs Revenue Market Share by Region (2015-2020)
Figure 16. Global Atrial Fibrillation Drugs Revenue Market Share by Region in 2019
Figure 17. Global Atrial Fibrillation Drugs Sales Share by Manufacturer in 2019
Figure 18. The Top 10 and 5 Players Market Share by Atrial Fibrillation Drugs Revenue in 2019
Figure 19. Atrial Fibrillation Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 20. Global Atrial Fibrillation Drugs Sales Market Share by Type (2015-2020)
Figure 21. Global Atrial Fibrillation Drugs Sales Market Share by Type in 2019
Figure 22. Global Atrial Fibrillation Drugs Revenue Market Share by Type (2015-2020)
Figure 23. Global Atrial Fibrillation Drugs Revenue Market Share by Type in 2019
Figure 24. Global Atrial Fibrillation Drugs Market Share by Price Range (2015-2020)
Figure 25. Global Atrial Fibrillation Drugs Sales Market Share by Application (2015-2020)
Figure 26. Global Atrial Fibrillation Drugs Sales Market Share by Application in 2019
Figure 27. Global Atrial Fibrillation Drugs Revenue Market Share by Application (2015-2020)
Figure 28. Global Atrial Fibrillation Drugs Revenue Market Share by Application in 2019
Figure 29. North America Atrial Fibrillation Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 30. North America Atrial Fibrillation Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 31. North America Atrial Fibrillation Drugs Sales Market Share by Country in 2019
Figure 32. North America Atrial Fibrillation Drugs Revenue Market Share by Country in 2019
Figure 33. U.S. Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 34. U.S. Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. Canada Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 36. Canada Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. North America Atrial Fibrillation Drugs Market Share by Type in 2019
Figure 38. North America Atrial Fibrillation Drugs Market Share by Application in 2019
Figure 39. Europe Atrial Fibrillation Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 40. Europe Atrial Fibrillation Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 41. Europe Atrial Fibrillation Drugs Sales Market Share by Country in 2019
Figure 42. Europe Atrial Fibrillation Drugs Revenue Market Share by Country in 2019
Figure 43. Germany Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 44. Germany Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. France Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 46. France Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. U.K. Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 48. U.K. Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Italy Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 50. Italy Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Russia Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 52. Russia Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Europe Atrial Fibrillation Drugs Market Share by Type in 2019
Figure 54. Europe Atrial Fibrillation Drugs Market Share by Application in 2019
Figure 55. Asia Pacific Atrial Fibrillation Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 56. Asia Pacific Atrial Fibrillation Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 57. Asia Pacific Atrial Fibrillation Drugs Sales Market Share by Region in 2019
Figure 58. Asia Pacific Atrial Fibrillation Drugs Revenue Market Share by Region in 2019
Figure 59. China Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 60. China Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Japan Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 62. Japan Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. South Korea Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 64. South Korea Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. India Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 66. India Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Australia Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 68. Australia Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Taiwan Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 70. Taiwan Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Indonesia Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 72. Indonesia Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Thailand Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 74. Thailand Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Malaysia Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 76. Malaysia Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Philippines Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 78. Philippines Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Vietnam Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 80. Vietnam Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Asia Pacific Atrial Fibrillation Drugs Market Share by Type in 2019
Figure 82. Asia Pacific Atrial Fibrillation Drugs Market Share by Application in 2019
Figure 83. Latin America Atrial Fibrillation Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 84. Latin America Atrial Fibrillation Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 85. Latin America Atrial Fibrillation Drugs Sales Market Share by Country in 2019
Figure 86. Latin America Atrial Fibrillation Drugs Revenue Market Share by Country in 2019
Figure 87. Mexico Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 88. Mexico Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Brazil Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 90. Brazil Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Argentina Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 92. Argentina Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Latin America Atrial Fibrillation Drugs Market Share by Type in 2019
Figure 94. Latin America Atrial Fibrillation Drugs Market Share by Application in 2019
Figure 95. Middle East and Africa Atrial Fibrillation Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 96. Middle East and Africa Atrial Fibrillation Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 97. Middle East and Africa Atrial Fibrillation Drugs Sales Market Share by Country in 2019
Figure 98. Middle East and Africa Atrial Fibrillation Drugs Revenue Market Share by Country in 2019
Figure 99. Turkey Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 100. Turkey Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Saudi Arabia Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 102. Saudi Arabia Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. U.A.E Atrial Fibrillation Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 104. U.A.E Atrial Fibrillation Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Middle East and Africa Atrial Fibrillation Drugs Market Share by Type in 2019
Figure 106. Middle East and Africa Atrial Fibrillation Drugs Market Share by Application in 2019
Figure 107. North America Atrial Fibrillation Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 108. North America Atrial Fibrillation Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 109. Europe Atrial Fibrillation Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 110. Europe Atrial Fibrillation Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Asia Pacific Atrial Fibrillation Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 112. Asia Pacific Atrial Fibrillation Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Latin America Atrial Fibrillation Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 114. Latin America Atrial Fibrillation Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Middle East and Africa Atrial Fibrillation Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 116. Middle East and Africa Atrial Fibrillation Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Porter's Five Forces Analysis
Figure 118. Channels of Distribution
Figure 119. Distributors Profiles
Figure 120. Bottom-up and Top-down Approaches for This Report
Figure 121. Data Triangulation
Figure 122. Key Executives Interviewed
心房細動（AF）診断の世界市場（～2026年） Atrial fibrillation (AF) is a type of cardiac arrhythmia which is caused by irregular electrical activities in the atria. It may occur with no symptoms but most common ones associated with it are fainting, palpitations, congestive failure of the heart or chest pain. Factors such as aging of populati…- 心房細動（AF）治療の世界市場（～2026年） Atrial fibrillation is an abnormal heart rhythm characterized by rapid and irregular beating of the atria. Often it starts as brief periods of abnormal beating which become longer and possibly constant over time. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting…
- 心房細動（SPAF）治療における脳卒中予防の世界市場（～2026年） Atrial fibrillation (AF) now a days has become a common and serious condition affecting almost 1-2% of the total population of age group 65 years and above. Increase in the aging population leads to increase in the prevalence further leads to increase rick of premature death. Market Analysis and Ins…
- 左心耳（LAA）閉鎖装置の世界市場（～2026年） Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF). On March 13, 2015, the U.S. Food and Drug Administration approved the WATCHM…
- 抗糖尿病治療薬の世界市場（～2026年） The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for…